Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Antimetabolites, Antineoplastic"" wg kryterium: Temat


Tytuł:
VEXAS syndrome: complete molecular remission after hypomethylating therapy.
Autorzy:
Sockel K; Medical Clinic and Policlinic I, University Hospital Dresden, TU Dresden, Dresden, Germany. .; German Cancer Consortium (DKTK), CHOICE Consortium, Partner Sites, MunichDresden, Germany. .
Götze K; German Cancer Consortium (DKTK), CHOICE Consortium, Partner Sites, MunichDresden, Germany.; Department of Medicine III, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.
Ganster C; Clinics of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.
Bill M; Medical Clinic and Policlinic I, University Hospital Dresden, TU Dresden, Dresden, Germany.
Georgi JA; Medical Clinic and Policlinic I, University Hospital Dresden, TU Dresden, Dresden, Germany.
Balaian E; Medical Clinic and Policlinic I, University Hospital Dresden, TU Dresden, Dresden, Germany.
Aringer M; Division of Rheumatology, Department of Medicine III, University Medical Center and Faculty of Medicine Carl Gustav Carus at the TU Dresden, Dresden, Germany.
Trautmann-Grill K; Medical Clinic and Policlinic I, University Hospital Dresden, TU Dresden, Dresden, Germany.
Uhlig M; Medical Clinic and Policlinic I, University Hospital Dresden, TU Dresden, Dresden, Germany.
Bornhäuser M; Medical Clinic and Policlinic I, University Hospital Dresden, TU Dresden, Dresden, Germany.; German Cancer Consortium (DKTK), CHOICE Consortium, Partner Sites, MunichDresden, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; National Center for Tumor Diseases (NCT/UCC), Dresden, Germany.
Haase D; Clinics of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.
Thiede C; Medical Clinic and Policlinic I, University Hospital Dresden, TU Dresden, Dresden, Germany.; AgenDix GmbH, Dresden, Germany.
Pokaż więcej
Źródło:
Annals of hematology [Ann Hematol] 2024 Mar; Vol. 103 (3), pp. 993-997. Date of Electronic Publication: 2024 Jan 12.
Typ publikacji:
Journal Article
MeSH Terms:
Antimetabolites, Antineoplastic*
Myelodysplastic Syndromes*/drug therapy
Skin Diseases, Genetic*
Humans ; Prospective Studies ; Azacitidine ; Pathologic Complete Response
SCR Disease Name:
VEXAS syndrome
Czasopismo naukowe
Tytuł:
Methotrexate level discrepancy post-glucarpidase: A pediatric case series and review of literature.
Autorzy:
Kibby D; Department of Pharmacy, AdventHealth for Children, Orlando, Florida, USA.
Trinkman H; Department of Pharmacy, Cook Children's Medical Center, Fort Worth, Texas, USA.
Pokaż więcej
Źródło:
Pediatric blood & cancer [Pediatr Blood Cancer] 2024 Mar; Vol. 71 (3), pp. e30831. Date of Electronic Publication: 2023 Dec 27.
Typ publikacji:
Review; Journal Article
MeSH Terms:
Methotrexate*/adverse effects
Antimetabolites, Antineoplastic*/adverse effects
Humans ; Child ; Chromatography, Liquid ; Tandem Mass Spectrometry ; gamma-Glutamyl Hydrolase/therapeutic use ; Recombinant Proteins
Czasopismo naukowe
Tytuł:
Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry study.
Autorzy:
Didi I; École Polytechnique, Palaiseau, France.
Alliot JM; Centre Hospitalo-Universitaire de Toulouse, Toulouse, France.
Dumas PY; Centre Hospitalier Universitaire de Bordeaux, Service d'Hématologie Clinique et de Thérapie Cellulaire, Bordeaux, France; Université de Bordeaux, Bordeaux, France; Institut National de la Santé et de la Recherche Médicale, U1035 Bordeaux, France.
Vergez F; Centre Hospitalo-Universitaire de Toulouse, Institut Universitaire du Cancer Toulouse-Oncopole, Laboratoire d'hématologie, Toulouse, France; Centre de Recherches en Cancérologie de Toulouse, Université Toulouse 3 Paul Sabatier, Toulouse, France.
Tavitian S; Centre Hospitalo-Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Service d'hématologie, Toulouse, France.
Largeaud L; Centre Hospitalo-Universitaire de Toulouse, Institut Universitaire du Cancer Toulouse-Oncopole, Laboratoire d'hématologie, Toulouse, France; Centre de Recherches en Cancérologie de Toulouse, Université Toulouse 3 Paul Sabatier, Toulouse, France.
Bidet A; CHU Bordeaux, Laboratoire d'Hématologie Biologique, F-33000 Bordeaux, France.
Rieu JB; Centre Hospitalo-Universitaire de Toulouse, Institut Universitaire du Cancer Toulouse-Oncopole, Laboratoire d'hématologie, Toulouse, France.
Luquet I; Centre Hospitalo-Universitaire de Toulouse, Institut Universitaire du Cancer Toulouse-Oncopole, Laboratoire d'hématologie, Toulouse, France.
Lechevalier N; CHU Bordeaux, Laboratoire d'Hématologie Biologique, F-33000 Bordeaux, France.
Delabesse E; Centre Hospitalo-Universitaire de Toulouse, Institut Universitaire du Cancer Toulouse-Oncopole, Laboratoire d'hématologie, Toulouse, France; Centre de Recherches en Cancérologie de Toulouse, Université Toulouse 3 Paul Sabatier, Toulouse, France.
Sarry A; Centre Hospitalo-Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Service d'hématologie, Toulouse, France.
De Grande AC; Centre Hospitalier Universitaire de Bordeaux, Service d'Hématologie Clinique et de Thérapie Cellulaire, Bordeaux, France.
Bérard E; Department of Epidemiology, Health Economics and Public Health, UMR 1295 CERPOP, University of Toulouse, INSERM, UPS, Toulouse University Hospital (CHU), Toulouse, France.
Pigneux A; Centre Hospitalier Universitaire de Bordeaux, Service d'Hématologie Clinique et de Thérapie Cellulaire, Bordeaux, France; Université de Bordeaux, Bordeaux, France.
Récher C; Centre de Recherches en Cancérologie de Toulouse, Université Toulouse 3 Paul Sabatier, Toulouse, France; Centre Hospitalo-Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Service d'hématologie, Toulouse, France.
Simoncini D; IRIT UMR 5505-CNRS, Université Toulouse I Capitole, Toulouse, France.
Bertoli S; Centre de Recherches en Cancérologie de Toulouse, Université Toulouse 3 Paul Sabatier, Toulouse, France; Centre Hospitalo-Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Service d'hématologie, Toulouse, France. Electronic address: .
Pokaż więcej
Źródło:
Leukemia research [Leuk Res] 2024 Jan; Vol. 136, pp. 107437. Date of Electronic Publication: 2024 Jan 09.
Typ publikacji:
Journal Article
MeSH Terms:
Antimetabolites, Antineoplastic*/therapeutic use
Leukemia, Myeloid, Acute*/diagnosis
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Humans ; Artificial Intelligence ; Treatment Outcome ; Azacitidine/therapeutic use ; Registries
Czasopismo naukowe
Tytuł:
Factors influencing methotrexate pharmacokinetics highlight the need for individualized dose adjustment: a systematic review.
Autorzy:
Yang Y; Department of Pharmacy, Shanghai Changhai Hospital, the First Affiliated Hospital of Navy Medical University, 168 Changhai Rd, Shanghai, 200433, China.
Liu Z; Department of Pharmacy, Shanghai Changhai Hospital, the First Affiliated Hospital of Navy Medical University, 168 Changhai Rd, Shanghai, 200433, China.
Chen J; Department of Pharmacy, Shanghai Changhai Hospital, the First Affiliated Hospital of Navy Medical University, 168 Changhai Rd, Shanghai, 200433, China.
Wang X; Department of Pharmacy, Shanghai Changhai Hospital, the First Affiliated Hospital of Navy Medical University, 168 Changhai Rd, Shanghai, 200433, China.
Jiao Z; Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University, 241 Huaihai West Road, Shanghai, 200030, China. .
Wang Z; Department of Pharmacy, Shanghai Changhai Hospital, the First Affiliated Hospital of Navy Medical University, 168 Changhai Rd, Shanghai, 200433, China. .
Pokaż więcej
Źródło:
European journal of clinical pharmacology [Eur J Clin Pharmacol] 2024 Jan; Vol. 80 (1), pp. 11-37. Date of Electronic Publication: 2023 Nov 07.
Typ publikacji:
Systematic Review; Meta-Analysis; Journal Article; Review
MeSH Terms:
Methotrexate*
Antimetabolites, Antineoplastic*
Adult ; Infant ; Infant, Newborn ; Humans ; Child
Czasopismo naukowe
Tytuł:
Efficacy and safety of an HDACi- and HMA-based protocol in adults with acute myeloid leukemia of intermediate- and adverse-risk categories: a retrospective study.
Autorzy:
Guo Z; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Guo D; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Kong D; Department of Hematology, The Fourth Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Bian S; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.; Institute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, People's Republic of China.
Lin L; Department of Hematology, Yantai Yuhuangding Hospital, Qingdao University Medical College, Yantai, People's Republic of China.
Fan S; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Li Q; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Zhao Y; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Jiang Y; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Yan J; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Wang Z; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Sun L; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Li Y; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Pokaż więcej
Źródło:
Hematology (Amsterdam, Netherlands) [Hematology] 2023 Dec; Vol. 28 (1), pp. 2219930.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Azacitidine*/adverse effects
Histone Deacetylase Inhibitors*/adverse effects
Leukemia, Myeloid, Acute*/metabolism
Antimetabolites, Antineoplastic*/adverse effects
Adult ; Humans ; Cytarabine/therapeutic use ; Decitabine/adverse effects ; Retrospective Studies
Czasopismo naukowe
Tytuł:
TIMP-2 as a predictive biomarker in 5-Fu-resistant colorectal cancer.
Autorzy:
Li Y; Department of Gastrointestinal Surgery, Shaoxing People's Hospital, Shaoxing, 312000, Zhejiang, China.
Xu C; Department of Gastrointestinal Surgery, Shaoxing People's Hospital, Shaoxing, 312000, Zhejiang, China.
Zhu R; Department of Emergency, Shaoxing People's Hospital, Shaoxing, 312000, Zhejiang, China.
Shen L; Department of Radiology, Shaoxing People's Hospital, Shaoxing, 312000, Zhejiang, China.
Hu G; Department of Gastrointestinal Surgery, Shaoxing People's Hospital, Shaoxing, 312000, Zhejiang, China.
Tao K; Department of Gastrointestinal Surgery, Shaoxing People's Hospital, Shaoxing, 312000, Zhejiang, China.
Tao F; Department of Gastrointestinal Surgery, Shaoxing People's Hospital, Shaoxing, 312000, Zhejiang, China. tf_.; Medical School of Shaoxing University, The First Hospital Affiliated to Shaoxing University, Shaoxing, 312000, Zhejiang, China. tf_.
Lu Z; Department of Radiology, Shaoxing People's Hospital, Shaoxing, 312000, Zhejiang, China. .; Medical School of Shaoxing University, The First Hospital Affiliated to Shaoxing University, Shaoxing, 312000, Zhejiang, China. .
Zhang G; Department of Gastrointestinal Surgery, Shaoxing People's Hospital, Shaoxing, 312000, Zhejiang, China. .
Pokaż więcej
Źródło:
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2023 Aug; Vol. 149 (10), pp. 7235-7246. Date of Electronic Publication: 2023 Mar 11.
Typ publikacji:
Journal Article
MeSH Terms:
Antimetabolites, Antineoplastic*/pharmacology
Antimetabolites, Antineoplastic*/therapeutic use
Colorectal Neoplasms*/drug therapy
Colorectal Neoplasms*/pathology
Tissue Inhibitor of Metalloproteinase-2*/therapeutic use
Animals ; Humans ; Biomarkers ; Cell Line, Tumor ; Drug Resistance, Neoplasm ; Fluorouracil/pharmacology ; Fluorouracil/therapeutic use
Czasopismo naukowe
Tytuł:
Physiologically Based Pharmacokinetic Modeling for Prediction of 5-FU Pharmacokinetics in Cancer Patients with Hepatic Impairment After 5-FU and Capecitabine Administration.
Autorzy:
Wang Y; Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, Cancer Center of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310006, China.
Hu H; Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, Cancer Center of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310006, China.
Yu L; Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, Cancer Center of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310006, China.
Zeng S; Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, Cancer Center of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310006, China. .
Pokaż więcej
Źródło:
Pharmaceutical research [Pharm Res] 2023 Sep; Vol. 40 (9), pp. 2177-2194. Date of Electronic Publication: 2023 Aug 23.
Typ publikacji:
Journal Article
MeSH Terms:
Antimetabolites, Antineoplastic*
Neoplasms*/drug therapy
Humans ; Capecitabine/therapeutic use ; Deoxycytidine ; Fluorouracil
Czasopismo naukowe
Tytuł:
Precision fluoropyrimidines dosing in a compound heterozygous variant carrier of the DPYD gene: a case report.
Autorzy:
Baiardi G; Clinical Pharmacology Unit, Ente Ospedaliero Ospedali Galliera, Mura Delle Cappuccine 14, 16128, Genoa, Italy. .; Pharmacology & Toxicology Unit, Department of Internal Medicine, University of Genoa, Viale Benedetto XV 2, 16132, Genoa, Italy. .
Clavarezza M; Medical Oncology Unit, Ente Ospedaliero Ospedali Galliera, Mura Delle Cappuccine 14, 16128, Genoa, Italy.
Stella M; Clinical Pharmacology Unit, Ente Ospedaliero Ospedali Galliera, Mura Delle Cappuccine 14, 16128, Genoa, Italy.; Pharmacology & Toxicology Unit, Department of Internal Medicine, University of Genoa, Viale Benedetto XV 2, 16132, Genoa, Italy.
Casazza S; Pathology Unit, Ente Ospedaliero Ospedali Galliera, Mura Delle Cappuccine 14, 16128, Genoa, Italy.
De Censi A; Medical Oncology Unit, Ente Ospedaliero Ospedali Galliera, Mura Delle Cappuccine 14, 16128, Genoa, Italy.
Mattioli F; Clinical Pharmacology Unit, Ente Ospedaliero Ospedali Galliera, Mura Delle Cappuccine 14, 16128, Genoa, Italy.; Pharmacology & Toxicology Unit, Department of Internal Medicine, University of Genoa, Viale Benedetto XV 2, 16132, Genoa, Italy.
Pokaż więcej
Źródło:
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2023 May; Vol. 91 (5), pp. 435-439. Date of Electronic Publication: 2023 Mar 08.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Fluorouracil*
Antimetabolites, Antineoplastic*/therapeutic use
Male ; Humans ; Middle Aged ; Capecitabine ; Dihydrouracil Dehydrogenase (NADP)/genetics ; Dihydrouracil Dehydrogenase (NADP)/metabolism ; Antimetabolites
Czasopismo naukowe
Tytuł:
Oral Capecitabine Exposures and Use of Uridine Triacetate: A 20-Year Retrospective Analysis.
Autorzy:
Seltzer JA; Division of Medical Toxicology, Department of Emergency Medicine, UC San Diego Health, 200 W. Arbor Dr. #8676, San Diego, CA, 92103, USA. .; California Poison Control System, San Diego, CA, USA. .; VA San Diego Healthcare System, San Diego, CA, USA. .
Friedman NA; Division of Medical Toxicology, Department of Emergency Medicine, UC San Diego Health, 200 W. Arbor Dr. #8676, San Diego, CA, 92103, USA.; California Poison Control System, San Diego, CA, USA.; VA San Diego Healthcare System, San Diego, CA, USA.
Hardin J; Division of Medical Toxicology, Department of Emergency Medicine, UC San Diego Health, 200 W. Arbor Dr. #8676, San Diego, CA, 92103, USA.; California Poison Control System, San Diego, CA, USA.; VA San Diego Healthcare System, San Diego, CA, USA.
Galust H; Division of Medical Toxicology, Department of Emergency Medicine, UC San Diego Health, 200 W. Arbor Dr. #8676, San Diego, CA, 92103, USA.; California Poison Control System, San Diego, CA, USA.; VA San Diego Healthcare System, San Diego, CA, USA.
Cantrell FL; Division of Medical Toxicology, Department of Emergency Medicine, UC San Diego Health, 200 W. Arbor Dr. #8676, San Diego, CA, 92103, USA.; California Poison Control System, San Diego, CA, USA.
Minns A; Division of Medical Toxicology, Department of Emergency Medicine, UC San Diego Health, 200 W. Arbor Dr. #8676, San Diego, CA, 92103, USA.; California Poison Control System, San Diego, CA, USA.
Pokaż więcej
Źródło:
Clinical drug investigation [Clin Drug Investig] 2023 May; Vol. 43 (5), pp. 359-363. Date of Electronic Publication: 2023 Apr 19.
Typ publikacji:
Journal Article
MeSH Terms:
Antimetabolites, Antineoplastic*/adverse effects
Genetic Predisposition to Disease*
Humans ; Middle Aged ; Capecitabine/adverse effects ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Dihydropyrimidine dehydrogenase phenotype in peripheral blood mononuclear cells is related to adverse events of fluoropyrimidine-therapy.
Autorzy:
Doornhof KR; Department of Clinical Pharmacy, Tergooi Medical Center, Hilversum, The Netherlands.
van der Linden PD; Department of Clinical Pharmacy, Tergooi Medical Center, Hilversum, The Netherlands.
Boeke GM; Department of Clinical Pharmacy, Tergooi Medical Center, Hilversum, The Netherlands.
Willemsen AECAB; Department of Internal Medicine, Tergooi Medical Center, Hilversum, The Netherlands.
Daskapan A; Department of Clinical Pharmacy, Tergooi Medical Center, Hilversum, The Netherlands. .
Pokaż więcej
Źródło:
European journal of clinical pharmacology [Eur J Clin Pharmacol] 2023 Apr; Vol. 79 (4), pp. 493-501. Date of Electronic Publication: 2023 Feb 09.
Typ publikacji:
Journal Article
MeSH Terms:
Dihydrouracil Dehydrogenase (NADP)*/genetics
Antimetabolites, Antineoplastic*
Humans ; Retrospective Studies ; Leukocytes, Mononuclear ; Prospective Studies ; Phenotype ; Fluorouracil/therapeutic use
Czasopismo naukowe
Tytuł:
Clinical Outcomes in Patients With Refractory Anemia With Excess Blasts (RAEB) Who Receive Hypomethylating Agents (HMAs).
Autorzy:
Zeidan AM; Department of Internal Medicine, Section of Hematology, Yale University School of Medicine and Yale Cancer Center, New Haven, CT. Electronic address: .
Mearns ES; Genentech, Inc., South San Francisco, CA.
Ng CD; Genentech, Inc., South San Francisco, CA.
Shah A; Genentech, Inc., South San Francisco, CA.
Lamarre N; Real World Data Analytics, Genesis Research, Hoboken, NJ.
Yellow-Duke A; Genentech, Inc., South San Francisco, CA.
Alrawashdh N; IQVIA, Falls Church, VA.
Yang B; Roche Diagnostics, Santa Clara, CA.
Cheng WH; AbbVie, North Chicago, IL.
Bui CN; AbbVie, North Chicago, IL.
Svensson A; AbbVie, North Chicago, IL.
Pokaż więcej
Źródło:
Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2024 Mar; Vol. 24 (3), pp. 177-186. Date of Electronic Publication: 2023 Oct 30.
Typ publikacji:
Journal Article
MeSH Terms:
Anemia, Refractory, with Excess of Blasts*/drug therapy
Leukemia, Myeloid, Acute*/drug therapy
Humans ; Aged ; United States/epidemiology ; Decitabine/pharmacology ; Decitabine/therapeutic use ; Antimetabolites, Antineoplastic/pharmacology ; Antimetabolites, Antineoplastic/therapeutic use ; Medicare ; Azacitidine/therapeutic use
Czasopismo naukowe
Tytuł:
ISG15 Promotes Progression and Gemcitabine Resistance of Pancreatic Cancer Cells Through ATG7.
Autorzy:
Meng Y; Department of Radiation Oncology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Bian L; Department of Radiation Oncology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Zhang M; Department of Radiation Oncology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Zhou P; Department of Radiation Oncology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Zhang S; Department of Emergency, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Ying Y; Department of Radiation Oncology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Yang S; Department of General Surgery, Shanghai university of TCM Shanghai TCM-integrated hospital, Shanghai, China.
Liu Y; Department of Chemotherapy, Nanjing Medical University Affiliated Cancer Hospital, Cancer Institute of Jiangsu Province, Nanjing, Jiangsu, China.
Yao Y; Department of Radiation Oncology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Li D; Department of Radiation Oncology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Pokaż więcej
Źródło:
International journal of biological sciences [Int J Biol Sci] 2024 Jan 21; Vol. 20 (4), pp. 1180-1193. Date of Electronic Publication: 2024 Jan 21 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Gemcitabine*
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/genetics
Pancreatic Neoplasms*/metabolism
Humans ; Deoxycytidine/pharmacology ; Deoxycytidine/therapeutic use ; Antimetabolites, Antineoplastic/pharmacology ; Antimetabolites, Antineoplastic/therapeutic use ; Cell Line, Tumor ; Drug Resistance, Neoplasm/genetics ; Ubiquitins/genetics ; Ubiquitins/pharmacology ; Ubiquitins/therapeutic use ; Cytokines/genetics
Czasopismo naukowe
Tytuł:
LogP of N-acyl-gemcitabine and lectin-corona emerge as key parameters in nanoparticulate intravesical cancer therapy.
Autorzy:
Anzengruber M; University of Vienna, Faculty of Life Sciences, Division of Pharmaceutical Technology and Biopharmaceutics, Josef-Holaubek-Platz 2, 1090 Vienna, Austria.
Wimmer L; University of Vienna, Faculty of Life Sciences, Division of Pharmaceutical Technology and Biopharmaceutics, Josef-Holaubek-Platz 2, 1090 Vienna, Austria.
Szuchar R; University of Vienna, Faculty of Life Sciences, Division of Pharmaceutical Technology and Biopharmaceutics, Josef-Holaubek-Platz 2, 1090 Vienna, Austria.
Skoll K; University of Vienna, Faculty of Life Sciences, Division of Pharmaceutical Technology and Biopharmaceutics, Josef-Holaubek-Platz 2, 1090 Vienna, Austria.
Wirth M; University of Vienna, Faculty of Life Sciences, Division of Pharmaceutical Technology and Biopharmaceutics, Josef-Holaubek-Platz 2, 1090 Vienna, Austria.
Gabor F; University of Vienna, Faculty of Life Sciences, Division of Pharmaceutical Technology and Biopharmaceutics, Josef-Holaubek-Platz 2, 1090 Vienna, Austria. Electronic address: .
Pokaż więcej
Źródło:
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences [Eur J Pharm Sci] 2023 Jan 01; Vol. 180, pp. 106330. Date of Electronic Publication: 2022 Nov 12.
Typ publikacji:
Journal Article
MeSH Terms:
Gemcitabine*/administration & dosage
Gemcitabine*/analogs & derivatives
Gemcitabine*/chemistry
Urinary Bladder Neoplasms*/drug therapy
Wheat Germ Agglutinins*/chemistry
Antimetabolites, Antineoplastic*/administration & dosage
Antimetabolites, Antineoplastic*/chemistry
Nanoparticle Drug Delivery System*/administration & dosage
Nanoparticle Drug Delivery System*/chemistry
Humans ; Administration, Intravesical ; Cell Line, Tumor ; Deoxycytidine/administration & dosage ; Polylactic Acid-Polyglycolic Acid Copolymer/chemistry
Czasopismo naukowe
Tytuł:
Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001.
Autorzy:
Ravandi F; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Döhner H; Ulm University Hospital, Ulm, Germany.
Wei AH; Peter MacCallum Cancer Centre, Melbourne, Australia.; The Royal Melbourne Hospital, Melbourne, Australia.
Montesinos P; Hematology Department, Hospital Universitari i Politècnic, La Fe, València, Spain.; CIBERONC, Instituto Carlos III, Madrid, Spain.
Pfeilstöcker M; Third Medical Department for Hematology and Oncology, Hanusch Hospital, Vienna, Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Papayannidis C; IRCCS, Azienda Ospedaliero Universitaria di Bologna, Istituto di Ematologia 'L. e A. Seràgnoli', Bologna, Italy.
Lai Y; Bristol Myers Squibb, Princeton, New Jersey, USA.
Wang K; Bristol Myers Squibb, Princeton, New Jersey, USA.
See WL; Bristol Myers Squibb, San Francisco, California, USA.
de Menezes DL; Bristol Myers Squibb, San Francisco, California, USA.
Petrlik E; Bristol Myers Squibb, Princeton, New Jersey, USA.
Prebet T; Bristol Myers Squibb, Summit, New Jersey, USA.
Roboz GJ; Weill Cornell Medicine, New York, New York, USA.
Pokaż więcej
Źródło:
British journal of haematology [Br J Haematol] 2024 Mar; Vol. 204 (3), pp. 877-886. Date of Electronic Publication: 2023 Nov 12.
Typ publikacji:
Journal Article
MeSH Terms:
Azacitidine*/therapeutic use
Leukemia, Myeloid, Acute*/drug therapy
Humans ; Antimetabolites, Antineoplastic/therapeutic use ; Neoplasm Recurrence, Local/drug therapy ; Remission Induction ; Chronic Disease ; Antimetabolites/therapeutic use
Czasopismo naukowe
Tytuł:
Prognostic value of RRM1 and its effect on chemoresistance in pancreatic cancer.
Autorzy:
Lin X; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, People's Republic of China.; Department of Gastroenterology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, People's Republic of China.
Tan Y; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, People's Republic of China.; Department of Gastroenterology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, People's Republic of China.
Pan L; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, People's Republic of China.; Department of Gastroenterology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, People's Republic of China.
Tian Z; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, People's Republic of China.; Department of Gastroenterology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, People's Republic of China.
Lin L; Department of Gastroenterology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, People's Republic of China.
Su M; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, People's Republic of China.; Department of Gastroenterology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, People's Republic of China.
Ou G; Department of Gastrointestinal Surgery, The Third-Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510600, People's Republic of China. .
Chen Y; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, People's Republic of China. .; Department of Gastroenterology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, People's Republic of China. .
Pokaż więcej
Źródło:
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2024 Mar; Vol. 93 (3), pp. 237-251. Date of Electronic Publication: 2023 Dec 01.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Gemcitabine*
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/genetics
Pancreatic Neoplasms*/metabolism
Humans ; Deoxycytidine/pharmacology ; Deoxycytidine/therapeutic use ; Prognosis ; Antimetabolites, Antineoplastic/therapeutic use ; Drug Resistance, Neoplasm ; Ribonucleoside Diphosphate Reductase
Czasopismo naukowe
Tytuł:
Impact of Folinic Acid Dosing on Efficacy and Toxicity of High-Dose Methotrexate in Central Nervous System Lymphoma.
Autorzy:
Haran A; Department of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, POB 12000, Jerusalem, 91120, Israel. Electronic address: .
Even-Zohar NG; Department of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, POB 12000, Jerusalem, 91120, Israel.
Haran M; Department of Hematology, Kaplan Medical Center, Rehovot, Israel.
Lebel E; Department of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, POB 12000, Jerusalem, 91120, Israel.
Aumann S; Department of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, POB 12000, Jerusalem, 91120, Israel.
Shaulov A; Department of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, POB 12000, Jerusalem, 91120, Israel.
Gatt M; Department of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, POB 12000, Jerusalem, 91120, Israel.
Nachmias B; Department of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, POB 12000, Jerusalem, 91120, Israel.
Pokaż więcej
Źródło:
Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2024 Mar; Vol. 24 (3), pp. 187-193.e1. Date of Electronic Publication: 2023 Oct 31.
Typ publikacji:
Journal Article
MeSH Terms:
Lymphoma*/drug therapy
Central Nervous System Neoplasms*/drug therapy
Humans ; Methotrexate/adverse effects ; Leucovorin/adverse effects ; Antimetabolites, Antineoplastic/therapeutic use ; Central Nervous System ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Adjuvant Capecitabine for Biliary Cancer and the Importance of Looking Beyond P-Values.
Autorzy:
Fojo AT; Department of Medicine, Division of Hematology Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA.
Neugut AI; Department of Medicine, Division of Hematology Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA.
Pokaż więcej
Źródło:
The oncologist [Oncologist] 2024 Feb 02; Vol. 29 (2), pp. 102-105.
Typ publikacji:
Editorial; Comment
MeSH Terms:
Biliary Tract Neoplasms*/drug therapy
Humans ; Capecitabine/therapeutic use ; Antimetabolites, Antineoplastic/therapeutic use
Opinia redakcyjna
Tytuł:
Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes.
Autorzy:
Merz AMA; Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Disease, University Hospital of Leipzig, Leipzig, Germany.
Sébert M; Service Hématologie Séniors, Hôpital Saint-Louis (AP-HP), Paris Cité University and INSERM U944, Paris, France.
Sonntag J; Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Disease, University Hospital of Leipzig, Leipzig, Germany.
Kubasch AS; Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Disease, University Hospital of Leipzig, Leipzig, Germany.
Platzbecker U; Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Disease, University Hospital of Leipzig, Leipzig, Germany. Electronic address: .
Adès L; Service Hématologie Séniors, Hôpital Saint-Louis (AP-HP), Paris Cité University and INSERM U944, Paris, France. Electronic address: .
Pokaż więcej
Źródło:
Cancer treatment reviews [Cancer Treat Rev] 2024 Feb; Vol. 123, pp. 102673. Date of Electronic Publication: 2023 Dec 19.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myelomonocytic, Chronic*/drug therapy
Myelodysplastic Syndromes*/drug therapy
Humans ; Antimetabolites, Antineoplastic/therapeutic use ; Azacitidine/therapeutic use ; Clinical Trials as Topic
Czasopismo naukowe
Tytuł:
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.
Autorzy:
Brunner AM; Massachusetts General Hospital, Boston, Massachusetts, USA.
Esteve J; Hospital Clínic, Barcelona, Spain.
Porkka K; Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
Knapper S; School of Medicine, Cardiff University, Cardiff, UK.
Traer E; Oregon Health & Science University, Portland, Oregon, USA.
Scholl S; University Hospital Jena, Jena, Germany.
Garcia-Manero G; MD Anderson Cancer Center, Houston, Texas, USA.
Vey N; Institut Paoli-Calmettes, Marseille, France.
Wermke M; TU Dresden, NCT/UCC Early Clinical Trial Unit, Dresden, Germany.
Janssen JJWM; Amsterdam University Medical Centers, Amsterdam, The Netherlands.
Narayan R; Massachusetts General Hospital, Boston, Massachusetts, USA.
Fleming S; The Alfred Hospital, Melbourne, Victoria, Australia.
Loo S; The Alfred Hospital, Melbourne, Victoria, Australia.
Tovar N; Hospital Clínic, Barcelona, Spain.
Kontro M; Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
Ottmann OG; School of Medicine, Cardiff University, Cardiff, UK.
Naidu P; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Sun H; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Han M; Cure Ventures, Boston, Massachusetts, USA.
White R; Novartis Ireland Limited, Dublin, Ireland.
Zhang N; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA.
Mohammed A; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Sabatos-Peyton CA; Larkspur Biosciences, Cambridge, Massachusetts, USA.
Steensma DP; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA.
Rinne ML; Blueprint Medicines, Cambridge, Massachusetts, USA.
Borate UM; Oregon Health & Science University, Portland, Oregon, USA.
Wei AH; The Peter MacCallum Cancer Centre and Royal Melbourne Hospital Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Pokaż więcej
Źródło:
American journal of hematology [Am J Hematol] 2024 Feb; Vol. 99 (2), pp. E32-E36. Date of Electronic Publication: 2023 Nov 22.
Typ publikacji:
Clinical Trial, Phase I; Letter
MeSH Terms:
Myelodysplastic Syndromes*/drug therapy
Leukemia, Myelomonocytic, Chronic*/drug therapy
Leukemia, Myeloid, Acute*/drug therapy
Antibodies, Monoclonal*
Humans ; Azacitidine/therapeutic use ; Decitabine/therapeutic use ; Antimetabolites, Antineoplastic/therapeutic use ; Hepatitis A Virus Cellular Receptor 2/therapeutic use ; Antibodies/therapeutic use ; Treatment Outcome
Raport
Tytuł:
Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).
Autorzy:
Usuki K; Department of Hematology, NTT Medical Center Tokyo, Higashi-Gotanda 5-9-22, Shinagawa-ku, Tokyo, 141-8625, Japan. .
Ohtake S; Kanazawa University, Kanazawa, Japan.
Honda S; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Matsuda M; PL General Hospital, Tondabayashi, Osaka, Japan.
Wakita A; Nagoya City University East Medical Center, Nagoya, Japan.
Nawa Y; Division of Hematology, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Takase K; Kyushu Medical Center, Fukuoka, Japan.
Maeda A; Hyogo Cancer Center, Akashi, Japan.
Sezaki N; Chugoku Central Hospital, Fukuyama, Japan.
Yokoyama H; National Hospital Organization Sendai Medical Center, Sendai, Japan.
Takada S; Leukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan.
Hirano D; Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Tomikawa T; Department of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
Sumi M; Nagano Red Cross Hospital, Nagano, Japan.
Yano S; Division of Clinical Oncology and Hematology, The Jikei University School of Medicine, Tokyo, Japan.
Handa H; Gunma University, Maebashi, Japan.
Ota S; Sapporo Hokuyu Hospital, Sapporo, Japan.
Fujita H; Department of Hematology, Yokohama Nanbu Hospital, Yokohama, Japan.
Fujimaki K; Department of Hematology, Fujisawa City Hospital, Kanagawa, Japan.
Mugitani A; Fuchu Hospital Division of Hematology, Osaka, Japan.
Kojima K; Department of Hematology, Kochi Medical School, Kochi University, Nankoku, Japan.
Kajiguchi T; Department of Hematology and Oncology, Tosei General Hospital, Seto, Japan.
Fujimoto K; Department of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Osaka, Japan.
Asou N; International Medical Center, Saitama Medical University, Hidaka, Japan.
Usui N; Department of Clinical Oncology and Hematology, The Jikei University Daisan Hospital, Tokyo, Japan.
Ishikawa Y; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Katsumi A; Department of Hematology, National Center for Geriatrics and Gerontology, Obu, Japan.
Matsumura I; Department of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Osaka, Japan.
Miyazaki Y; Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
Kiyoi H; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Pokaż więcej
Źródło:
International journal of hematology [Int J Hematol] 2024 Feb; Vol. 119 (2), pp. 130-145. Date of Electronic Publication: 2023 Dec 13.
Typ publikacji:
Observational Study; Multicenter Study; Journal Article
MeSH Terms:
Leukemia, Myelomonocytic, Chronic*/drug therapy
Leukemia, Myelomonocytic, Chronic*/epidemiology
Myelodysplastic Syndromes*/drug therapy
Myelodysplastic Syndromes*/epidemiology
Leukemia, Myeloid, Acute*/drug therapy
Male ; Humans ; Japan/epidemiology ; Antimetabolites, Antineoplastic/therapeutic use ; Azacitidine/therapeutic use
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies